Research And Markets: Will High Volume Usage Of Hormonal Therapies Make Japan An Important Country In Which To Market Effective, Low Toxicity Drugs?
Posted on: Wednesday, 16 February 2005, 12:00 CST
Prostate cancer is the most common male malignancy in Western countries. Increasing usage of screening and changes in treatment practice means companies will have to adapt to exploit the market. We have Prostate Cancer Insight details physician opinion of currently available products and disease management practice and what they require in the future.
Research and Markets (http://www.researchandmarkets.com/reports/c12962) has announced the addition of Stakeholder Insight: Prostate Cancer Treatment and Commercial Issues to their offering
The scope of this report is as follows:
-- Quantitative treatment data from over 440 physicians: 60 from Japan, France, Germany, Italy, Spain and the UK, and 80 from the US
-- Qualitative feedback on key findings and future trends in the treatment of prostate cancer and the management of disease and treatment side effects
-- Analysis of leading companies in the prostate cancer market and the commercial challenges and opportunities ahead.
The highlights of this report are as follows
-- AstraZeneca is promoting Casodex monotherapy heavily in non-metastatic disease as an alternative to an LHRH agonist. Approval for Casodex monotherapy has been delayed in some markets, but physicians are already prescribing off-label, especially in patients with dementia, a condition that can be exacerbated by the use of LHRH agonists.
-- In Japan the volume usage of hormonal drug therapy is far more common as the average age of the patient is well over 70 and so curative treatment is often contraindicated. We believe the high volume usage of hormonal therapies makes this an important country in which to market effective, low toxicity drugs.
Clinical trials have shown the lack of activity of estramustine in hormone refractory prostate cancer, but the drug is still commonly used because of the lack of alternatives. Recent trial results of estramustine in combination with Aventis Taxotere show much greater efficacy and usage of this combination is already significant.
Reasons to Purchase this report:
-- Identify hot topics and key issues for practicing prostate cancer specialists the questions they really want answered
-- Predict future trends in the treatment of prostate cancer and how to capitalize on forthcoming changes in treatment practice
-- Plan product development to fill prostate cancer market niches as defined by practicing physicians
The contents of this report are as follows: -0- *T Chapter 1 Executive Summary 4 Chapter 2 Introduction 29 Chapter 3 Screening, Diagnosis And Staging 38 Chapter 4 Treatment Strategy 63 Chapter 5 Side Effects And Supportive Care 136 Chapter 6 Commercial Analysis 170 Chapter 7 Supporting Data 183 Chapter 8 Appendix A 196 Chapter 9 Appendix B: 287 *T
For more information visit http://www.researchandmarkets.com/reports/c12962
Source: Business Wire
Related Articles
- Family Practice Physicians Martin Devine, Leah Doret, Elizabeth Fuller and Monika Mathur Join Harrington Physician Services in Charlton
- Misys First to Meet ISDA Market Practice Changes for CDS in Asia
- Ogilvy Public Relations Worldwide Names Liz Van Lenten Executive Vice President and Group Director of Chicago's Consumer Marketing Practice
- Bill Reihl to Lead Ogilvy Public Relations Worldwide NY Consumer Marketing Practice
- Recession Marketing Practice Launched by Ogilvy
- Latest Most Up-to-Date Cancer Personalized Medicine Market Report
- Key Challenges and Issues Facing the Cancer Cell Therapy Markets
- An Aging Population, Technological Change and Growth in Household Incomes Will Bode Well for General and Family Practice Physicians in the US
- Research and Markets : Cancer Drug Discoveries: What the Future Holds: Breast Cancer Chapter
- Nymox Records Minimal Side Effects in Prostate Treatment
 |
 |
User Comments (0)
RSS Feeds